Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Cynata Therapeutics Limited ( (AU:CYP) ).
Cynata Therapeutics has completed the 100-day primary evaluation period for all 65 participants in its Phase 2 trial of CYP-001 in adults with acute graft versus host disease, marking the last-patient, last-visit milestone in this randomized, double-blind, placebo-controlled study. With data now being compiled and analyzed ahead of a results readout expected in June 2026, the outcome will be closely watched given CYP-001’s prior strong Phase 1 results, FDA Orphan Drug Designation, and the severe unmet need in aGvHD, while Cynata’s broader pipeline, including a Phase 3 osteoarthritis trial and a kidney transplant study, continues to advance on schedule.
The completion of this key evaluation window reinforces Cynata’s position as a leading developer of iPSC-derived cell therapeutics and could materially influence its clinical strategy, regulatory path, and partnering prospects if the Phase 2 data confirm earlier efficacy and safety signals. Concurrently, the on-track timelines for its Phase 3 CYP-004 osteoarthritis study and the progressing NEREID kidney transplantation trial highlight a diversified late-stage pipeline that may expand the company’s future commercial opportunities across multiple high-need indications.
The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company focused on stem cell and regenerative medicine therapies based on its proprietary Cymerus platform. The technology uses induced pluripotent stem cells to economically manufacture mesenchymal stem cell products at commercial scale, targeting indications such as acute graft versus host disease, diabetic foot ulcers, osteoarthritis, and kidney transplantation.
YTD Price Performance: -13.04%
Average Trading Volume: 274,141
Technical Sentiment Signal: Hold
Current Market Cap: A$71.24M
See more insights into CYP stock on TipRanks’ Stock Analysis page.